KR20220047807A - 근육 소모 및 다른 상태의 치료 및 예방에 적합한 화합물 - Google Patents

근육 소모 및 다른 상태의 치료 및 예방에 적합한 화합물 Download PDF

Info

Publication number
KR20220047807A
KR20220047807A KR1020227007940A KR20227007940A KR20220047807A KR 20220047807 A KR20220047807 A KR 20220047807A KR 1020227007940 A KR1020227007940 A KR 1020227007940A KR 20227007940 A KR20227007940 A KR 20227007940A KR 20220047807 A KR20220047807 A KR 20220047807A
Authority
KR
South Korea
Prior art keywords
compound
group
methyl
formula
muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227007940A
Other languages
English (en)
Korean (ko)
Inventor
폴커 아담스
지크프리드 라바이트
Original Assignee
폴커 아담스
지크프리드 라바이트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 폴커 아담스, 지크프리드 라바이트 filed Critical 폴커 아담스
Publication of KR20220047807A publication Critical patent/KR20220047807A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020227007940A 2019-08-16 2020-08-14 근육 소모 및 다른 상태의 치료 및 예방에 적합한 화합물 Ceased KR20220047807A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19192107.1 2019-08-16
EP19192107 2019-08-16
PCT/EP2020/072911 WO2021032643A1 (en) 2019-08-16 2020-08-14 Compounds suitable for the treatment and prophylaxis of muscle wasting and other conditions

Publications (1)

Publication Number Publication Date
KR20220047807A true KR20220047807A (ko) 2022-04-19

Family

ID=67659191

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227007940A Ceased KR20220047807A (ko) 2019-08-16 2020-08-14 근육 소모 및 다른 상태의 치료 및 예방에 적합한 화합물

Country Status (13)

Country Link
US (1) US12331042B2 (https=)
EP (1) EP4013497B1 (https=)
JP (1) JP2022544803A (https=)
KR (1) KR20220047807A (https=)
CN (1) CN114302881B (https=)
AU (1) AU2020334194A1 (https=)
BR (1) BR112022002769A2 (https=)
CA (1) CA3144700A1 (https=)
CL (1) CL2022000320A1 (https=)
IL (1) IL290540A (https=)
MX (1) MX2022002022A (https=)
WO (1) WO2021032643A1 (https=)
ZA (1) ZA202202863B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240031608A (ko) * 2022-09-01 2024-03-08 단국대학교 천안캠퍼스 산학협력단 퓨로크로멘온계 화합물을 유효성분으로 포함하는 근감소증 예방 또는 치료용 약학 조성물

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023348158A1 (en) * 2022-09-30 2025-02-27 Société des Produits Nestlé S.A. Composition and method for treating muscle decline associated with renal disease or dysfunction

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2624524C (en) * 2005-09-29 2014-07-08 Elan Pharmaceuticals, Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4
EP2072528A1 (en) 2007-12-19 2009-06-24 Labeit, Mr. Siegfried A host cell deficient for MuRF1 and MuRF2
WO2012154213A1 (en) * 2011-04-07 2012-11-15 Cornell University Cofluorons and methods of making and using them
AU2012268036B2 (en) * 2011-06-06 2017-04-06 THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF STATE OF THE DEPARTMENT OF VETERANS AFFAIRS Methods of inhibiting muscle atrophy
AU2014290368B2 (en) 2013-07-18 2019-07-11 Baylor College Of Medicine Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
WO2015050984A1 (en) * 2013-10-01 2015-04-09 New York University Amino, amido, and heterocyclic compounds as modulators of rage activity and uses thereof
CN112274183A (zh) * 2020-11-02 2021-01-29 李云莹 一种神经内科用脑部超声波治疗装置

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240031608A (ko) * 2022-09-01 2024-03-08 단국대학교 천안캠퍼스 산학협력단 퓨로크로멘온계 화합물을 유효성분으로 포함하는 근감소증 예방 또는 치료용 약학 조성물

Also Published As

Publication number Publication date
AU2020334194A1 (en) 2022-02-24
US12331042B2 (en) 2025-06-17
WO2021032643A1 (en) 2021-02-25
JP2022544803A (ja) 2022-10-21
EP4013497B1 (en) 2023-10-04
EP4013497C0 (en) 2023-10-04
EP4013497A1 (en) 2022-06-22
US20220324852A1 (en) 2022-10-13
CN114302881B (zh) 2025-03-25
CN114302881A (zh) 2022-04-08
CL2022000320A1 (es) 2023-02-03
ZA202202863B (en) 2023-10-25
CA3144700A1 (en) 2021-02-25
MX2022002022A (es) 2022-05-11
BR112022002769A2 (pt) 2022-05-10
IL290540A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
JP5618548B2 (ja) イミダゾ［１，２−ａ］ピリジンおよびそれらの薬剤としての使用
US8481553B2 (en) Antimetastatic compounds
SK286513B6 (sk) Použitie 4-Fluór-N-indan-2-ylbenzamidu na výrobu liečiva
JP2018502097A (ja) 二官能性分子によって標的化タンパク質分解を誘導する方法
WO2010139180A1 (zh) 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
BR112016009488B1 (pt) piperidil-etil-pirimidina substituída, seus usos, e composição farmacêutica
JP2017511333A (ja) ラミノパシー、老化及び癌を治療又は予防するためのｎａｔ１０モジュレーター
ES2930106T3 (es) Compuesto derivado de pirrol-piridina, procedimiento para preparar el mismo y composición farmacéutica que contiene el mismo como ingrediente activo para la prevención o el tratamiento de enfermedades relacionadas con la proteína quinasa
CN107074839A (zh) 用于治疗代谢和体重相关的病症的组合物和方法
KR20220163435A (ko) 피라졸릴프로판아미드 화합물 및 전립선암의 치료에서의 그 용도
WO2018053373A1 (en) Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
BR112021000938A2 (pt) composto sal farmaceuticamente aceitável, tautômero, isômero ou estereoisômero do mesmo, composição farmacêutica e processo para a síntese do dito composto
US12331042B2 (en) Compounds suitable for the treatment and prophylaxis of muscle wasting and other conditions
US20160008339A1 (en) Psoralen derivatives for preventing or treating heart failure or cardiac hypertrophy
US20220387359A1 (en) Synergistic inhibitors of creb-mediated gene transcription
CN101659659B (zh) 嘧啶衍生物及其医药用途
US20130338116A1 (en) Compounds and methods for the treatment of pain and other diseases
CN106831747A (zh) 五元杂环取代的n-烷基酰胺类wnt通路抑制剂
WO2018145217A1 (en) Human ets-related gene (erg) compounds as therapeutics and methods for their use
WO2012056976A1 (ja) アデニル酸シクラーゼの活性調節剤
JP2019535826A (ja) 心血管疾患及び肺疾患を治療するためのグルコース−６−リン酸デヒドロゲナーゼの阻害剤
CN109134433B (zh) 一种抑制rock的化合物及其应用
CN109758459B (zh) 取代的吡啶的新用途
US20240150286A1 (en) PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPARy) LIGANDS AND METHODS OF USE AS TREATMENTS FOR INSULIN RESISTANCE, OBESITY, FATTY LIVER DISEASE, AND TYPE 2 DIABETES
KR20230116716A (ko) 심부전 (Heart Failure)의 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601